LLY
NYSE · Pharmaceuticals
Eli Lilly and Co.
$1,152.93
+0.49 (+0.04%)
LLY News30 articles
Eli Lilly's Inluriyo-Verzenio Combo Gains FDA Nod, Shares Steady
FDA approved Eli Lilly's Inluriyo-Verzenio combo for ESR1-mutated breast cancer. Shares closed nearly flat at $1,152.93 as the approval expands an existing franchise.
Twist Bioscience Surges 11% on Lilly TuneLab Pact, Yet Financial Terms Remain Vague
Twist Bioscience shares rose 10.8% following a partnership with Eli Lilly's TuneLab, but the lack of disclosed financial terms leaves the deal's revenue impact uncertain.
ATAI Stock Holds at $7.28 as Lilly Deal Nears Close; CVR Value Priced at 53 Cents
ATAI shares closed at $7.28 after shareholders approved Eli Lilly's takeover. The market values the contingent value right at 53 cents, a fraction of its $2.50 maximum.
Pfizer Stock Hits 52-Week High at 10x Forward Earnings
Pfizer shares climbed 1.7% to $29.04, hitting a 52-week high, as the stock trades at 10x projected 2026 earnings, with a 5.9% dividend yield.
Kailera Shares Slip 12.5%, Valuation Nears Cash Position
Kailera shares dropped 12.5% to $16.21, leaving valuation barely above IPO price and close to cash per share. Pipeline catalysts in 2027.
Lilly Stock Slips Despite Mounjaro Heart Approval
Eli Lilly shares dipped 0.9% despite FDA approval for Mounjaro to cut heart risks, as investors had already priced in the news. Sales still surged 91%.
Eli Lilly Stock Nears Analyst Targets After $67B Rally
Eli Lilly's shares have rallied 6.38% over the past week, adding $67B in market value, bringing the stock within 4.4% of analysts' consensus target.
Eli Lilly Stock Near Record as Volume Surge Offsets Price Cuts
Eli Lilly (LLY) nears all-time high as Q2 volume surges 60%, offsetting a 13% price drop. Mounjaro and Zepbound account for 64% of revenue.
Novo Nordisk Gains 1.9% as Medicare Wegovy Copay Trial Raises Pricing Questions
Novo Nordisk's ADR gained 1.85% to $45.71 as Medicare's GLP-1 Bridge offers Wegovy at $50 monthly, but analysts see limited upside with all Holds.
Novo Nordisk Outlook Upgrade Fails to Lift Shares as Analysts See Slim Gains
Novo Nordisk stock slipped 2.9% last week even after management raised its 2026 guidance. Analysts see only 2.2% upside, with most rating the stock a Hold.
XLV Retreats from Record as Mid-Sized Health Care Names Lag
XLV hit a record $169.71 before closing lower, lagging the S&P 500 by 0.74 points. Weakness among smaller health care holdings offset gains in top components.
Eli Lilly Defends Obesity Drug Pipeline Amid Retatrutide Lawsuits
Eli Lilly shares rose 0.5% as the company filed six lawsuits against unauthorized sellers of its experimental obesity drug retatrutide, reinforcing its commitment to pipeline integrity.
Bristol Myers Unveils $2.3B Houston Facility for Flexible Drug Production
Bristol Myers Squibb (BMY) will build a $2.3 billion drug-manufacturing campus in Houston, supporting small molecules, biologics, and antibody-drug conjugates, with nearly 500 skilled jobs.
Lilly's Foundayo Wins UK Approval, Lifting Shares Nearly 3%
Eli Lilly's (LLY) shares jumped 2.9% after the UK became the first European country to approve its oral weight-loss drug Foundayo, adding about $30 billion to its market value.
J&J Shares Hold Ground Despite 5.5% EPS Guidance Cut
Johnson & Johnson (NYSE:JNJ) closed at $259.24 on Friday, up 0.9%, despite a 5.5% cut to its 2026 adjusted EPS guidance. Investors appear to view the dilution as pipeline investment.
Pfizer Stock Rises as Core Drug Growth Offsets COVID Decline
Pfizer (PFE) shares rose 0.9% after Q2 results beat estimates, with non-COVID drug growth offsetting a steep decline in COVID product sales.
Dow Advances as Tech Spending Bets Fuel Mixed Market Close
The Dow advanced on AI spending expectations, while the Nasdaq slipped. Amgen, Lilly, and Disney rose; SpaceX and AMD fell. Markets await Friday's jobs report.
Dow Rises on Rate-Sensitive Gains While Market Breadth Weakens
The Dow gained 0.87% even as private payrolls missed forecasts and ISM prices jumped. Nasdaq and small caps declined, with weak breadth and healthcare outperforming tech.
Pfizer Stock Rises as Non-COVID Drugs Offset Pandemic Revenue Slump
Pfizer's Q2 beat estimates as four growth brands offset COVID revenue declines. Shares rose 1.48% premarket.
Stock Futures Rise as Investors Favor AI Profitability Over Spending
US stock futures advanced as investors differentiated between AI companies with strong earnings and those with heavy spending, with Nvidia and Arista Networks gaining.
CVS Raises Guidance as Aetna Powers Q2 Beat
CVS Health raised its 2026 EPS outlook after a strong Q2, with Aetna contributing nearly all of the operating-profit increase. The stock rose in premarket trading.
Lilly's Q2 Growth Hinges on Mounjaro, Zepbound as Sales Projection Leans Heavily on Weight-Loss Franchise
Eli Lilly (LLY) is set to report Q2 earnings Wednesday, with Mounjaro and Zepbound expected to contribute 98% of revenue growth. Pre-market shares rose 2.2% after a five-day slide.
Novo Nordisk Slips 4% as Profit Beat Fails to Quell Wegovy Worries
Novo Nordisk shares dropped 4% in Copenhagen after Q2 profit beat estimates, but concerns over Wegovy and pipeline setbacks weighed on sentiment.
Amgen Lifts 2026 Forecast as Five Growth Brands Offset $772M Slump
Amgen (AMGN) raised its 2026 guidance after Q2 revenue beat estimates, as five growth brands added $923M in sales, offsetting a $772M decline from five struggling products.
Novo Nordisk ADR Slides Despite Strong Q2, Danish Shares Await Catch-Up
Novo Nordisk's ADR dropped 6.8% despite Q2 earnings surpassing forecasts, as investors weigh pipeline impairments and competitive pressures.
Stock Futures Climb as Oil Slumps Ahead of Key Jobs Report and AI Earnings
US stock futures advanced Monday as oil prices plunged over 6% on diplomatic hopes, while investors braced for July jobs data and a busy week of major tech earnings.
AZN-BMY Merger Talks: A $455B Pharma Mega-Deal in the Making?
AstraZeneca and Bristol Myers Squibb are reportedly in merger talks, which could create a $455 billion pharmaceutical giant. Reuters has not confirmed the report.
Wall Street Kicks Off August with Modest Gains Ahead of Jobs Report
The S&P 500 gained 0.7% on Friday, though declining stocks outnumbered advancers. Investors await July payrolls data, with Amazon leading gains while Apple fell.
Tech Gains Mask Narrow Market as Jobs Report Looms
Stocks closed higher this week, but tech-led gains masked a narrow rally. Investors now await the July jobs report, which could influence Fed rate hike expectations.
AI Cash Flow Concerns Split Tech Stocks as S&P 500 Gains 1.1%
Wall Street ended higher last week, but AI investment scrutiny deepened. Microsoft and Amazon rallied on strong cloud results, while Apple and Meta slid on cash flow worries.